Overview

Expanded Access Program of AMN107 in Imatinib-resistant or Intolerant Adult Patients With Chronic Myeloid Leukemia

Status:
No longer available
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This study will further evaluate if AMN107 is safe in adults with chronic myeloid leukemia who are resistant or intolerant to imatinib and to provide patients access to this new drug until the drug becomes commercially available.
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
Imatinib Mesylate